Analyst Reco. NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-05 pm EST			5-day change	1st Jan Change
12.77 ^USD	-1.69%		+4.67%	-82.59%

Nov. 29	Transcript : NovoCure Limited Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 03:30 PM	CI
Nov. 28	Sector Update: Health Care Stocks Ease Tuesday Afternoon	MT

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	Oct. 26	MT
Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	Aug. 29	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	Aug. 28	MT
HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	Aug. 28	MT
Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	Aug. 28	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	Aug. 28	MT
Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45	Aug. 08	MT
SVB Securities Initiates NovoCure at Outperform With $51 Price Target	Aug. 04	MT
Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33	Jul. 31	MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	Jun. 07	MT
Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating	Jun. 07	MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	Jun. 07	MT
Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $104 From $70	May. 16	MT
Wedbush Cuts NovoCure's Price Target to $53 From $65 After Lower-Than-Expected Q1 Results, Keeps Underperform Rating	May. 05	MT
JPMorgan Downgrades NovoCure to Underweight From Neutral, Adjusts Price Target to $50 From $99	Mar. 17	MT
Piper Sandler Adjusts NovoCure's Price Target to $80 From $70, Maintains Neutral Rating	Jan. 17	MT
JPMorgan Adjusts NovoCure's Price Target to $99 From $86, Keeps Neutral Rating	Jan. 06	MT
Wells Fargo Downgrades NovoCure to Equalweight From Overweight, Adjusts Price Target to $107 From $89	Jan. 06	MT
HC Wainwright Adjusts NovoCure's Price Target to $140 From $100, Maintains Buy Rating	Jan. 05	MT
Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $89 From $74	Nov. 29	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Analyst Reco.

Filters